Giovanni Caforio, Chairman and Chief Executive Officer Bristol-Myers Squibb

Our Response to COVID-19

A Letter from CEO and Chairman, Giovanni Caforio, M.D.

The global spread of COVID-19 is affecting each of us and the communities in which we live in different ways. Bristol Myers Squibb is proactively taking steps to promote public health and carry out our mission of providing life-saving medicines to the patients who depend on us.
 
 

More on Our Response

For Clinical Trial Investigators

For Clinical Trial Investigators

For Media

For Media

For U.S. Healthcare Professionals

For U.S. Healthcare Professionals

For Investors

For Investors

For Patient Advocacy Groups

For Patient Advocacy Groups

Frequently Asked Questions

How is COVID-19 affecting the supply of Bristol Myers Squibb medicines?

Triangle Icon

How is COVID-19 affecting Bristol Myers Squibb clinical trials and ongoing research efforts?

Triangle Icon

How is Bristol Myers Squibb protecting its workforce?

Triangle Icon

How is Bristol Myers Squibb protecting healthcare providers?

Triangle Icon

Where can patients go for questions about COVID-19 and Bristol Myers Squibb medicines?

Triangle Icon

How is Bristol Myers Squibb contributing to the global relief efforts for COVID-19?

Triangle Icon

How do I reach the media team at Bristol Myers Squibb?

Triangle Icon

Where can I find more information about how the pharmaceutical industry’s response to COVID-19?

Triangle Icon

Where can I go for more information about COVID-19?

Triangle Icon